Table 3.
Encounters (N=361)
| Percentage of n=361 encounters | Percentage where there was provider activity communication – unadjusted | p-value1 | Odds Ratio for PA communication (95 CI) – adjusted analysis | p-value2 | |
|---|---|---|---|---|---|
| Clinician Gender | |||||
| Female | 243 (67%) | 34% | p=0.64 | Reference | |
| Male | 120 (33%) | 37% | 1.14 (0.36, 3.6) | p=0.82 | |
| Clinician Training | |||||
| MD/DO | 234 (65%) | 34% | p=0.57 | Reference | |
| NP/PA | 129 (35%) | 37% | 0.60 (0.21, 1.74) | p=0.35 | |
| Clinician Specialty | |||||
| Medical Oncology | 172 (47%) | 55% | p<0.0001 | ||
| Radiation Oncology | 71 (20%) | 13% | |||
| Surgical Oncology | 94 (26%) | 19% | |||
| Urology | 24 (7%) | 21% | |||
| Disease Site | |||||
| Breast | 271 (75%) | 37% | p=0.20 | Reference | |
| Colon | 32 (9%) | 38% | 0.38 (0.09, 1.67) | p=0.20 | |
| Prostate | 60 (17%) | 25% | 0.17 (0.02, 1.32) | p=0.09 | |
| Patient Gender | |||||
| Female | 289 (80%) | 37% | p=0.22 | Reference | |
| Male | 74 (20%) | 28% | 1.46 (0.28, 7.54) | p=0.65 | |
| Patient Race | |||||
| White | 254 (70%) | 35% | p=0.21 | Reference | |
| AA | 81 (22%) | 40% | 1.31 (0.72, 2.39) | p=0.37 | |
| Other/unknown | 28 (8%) | 21% | |||
| Patient Age Group | |||||
| <50 | 89 (25%) | 23% | p<0.001 | 1.41 (1.11, 1.81) | p=0.006 |
| 50–59 | 104 (29%) | 34% | |||
| 60–69 | 95 (26%) | 40% | |||
| 70–79 | 53 (15%) | 45% | |||
| >80 | 20 (6%) | 50% | |||
| Current Treatment | |||||
| Surveillance | 79 (22%) | 46% | p<0.0001 | 0.96 (0.43, 2.13) | p=0.92 |
| Surgery | 101 (28%) | 19% | 0.2 (0.08, 0.5) | p<0.001 | |
| Chemotherapy | 35 (10%) | 37% | 0.52 (0.2, 1.33) | p=0.17 | |
| Radiation | 53 (15%) | 6% | 0.06 (0.01, 0.29) | p<0.001 | |
| Endocrine | 93 (26%) | 58% | Reference |
1
: p-value from Fisher’s exact test
2
: p-value from multivariable model accounting for correlation within clinician